FDAs 2025 Increase in Warning Letters on Compounded Drug Advertising In recent remarks at the Food and Drug Law Institutes Enforcement, Litigation, and Compliance Conference, the director of the Office of Compliance within FDAs Center for Drug Evaluation and Research's (CDER) noted that 22% of warning letters that CDER issued in fiscal year (FY) 2025 were sent to telehealth platforms and other entities related to claims made regarding compounded drug products, including compounded GLP-1s
Understanding potential interactions, safety considerations, and when to consult your healthcare provider is essential before combining these substances
Many people starting a GLP-1 program report initial nausea, bloating, or a heavy feeling in the stomach as their body adjusts
How To Create Your Perfect, Simple Semaglutide Support Program I'm confident that if you've read this article and you follow my simple suggestions, you'll be aware of the common semaglutide/GLP-1 agonist side effects and know how to avoid them
RELATED: Wegovy vs
doi:10.1074/jbc.M304034200 Salehi B, Imani R, Mohammadi MR, et al